Browse the corpus

The 9-valent human papillomavirus (HPV) vaccine (9vHPV) is a second-generation, noninfectious, recombinant vaccine available in the United States and indicated for the management and prevention of infections, diseases, or cancers caused by both low-risk and high-risk HPV types, including 6, 11, 16, 18, 31, 33, 45, 52, and 58. HPVs are the leading sexually transmitted viruses responsible for precancerous and cancerous lesions. The 9vHPV has been licensed by the US Food and Drug Administration (FDA) since 2014 and is classified as a preventive immunization. The exact mechanism of action of 9vHPV remains unclear, as HPV only affects humans, which poses challenges for research. However, researchers hypothesize that the vaccine operates by triggering the humoral response. This activity comprehensively examines the indications, actions, and contraindications of the 9vHPV vaccine as a crucial tool in managing and preventing HPV infection and associated diseases. Furthermore, this activity underscores the mechanism of action, adverse event profile, and other essential considerations regarding administering the 9vHPV vaccine, which is crucial for clinicians in delivering HPV immunization to patients effectively. Objectives: Identify individuals eligible for the human papillomavirus vaccine (9vHPV) based on current guidelines, considering age, gender, and other relevant factors. Differentiate between the various human papillomavirus vaccines (HPV) available, including the bivalent, quadrivalent, and 9-valent formulations, based on their indications, dosing schedules, and target HPV types. Implement evidence-based protocols for administering the human papillomavirus vaccine, ensuring adherence to recommended dosing schedules and administration routes. Collaborate with other healthcare providers, such as pharmacists, nurses, and public health officials, to promote human papillomavirus vaccination initiatives and ensure comprehensive vaccination coverage within the community. Access free multiple choice questions on this topic.

9vHPV is a generally well-tolerated vaccine with a robust safety profile. The most common adverse effects are minor issues such as injection-site pain, swelling, erythema, and tenderness.[14] Minor systemic effects have been reported, such as headaches, pyrexia, fatigue, and nausea.[15] Toxic effects are attributable to anaphylaxis and hypersensitivity reactions. In the case of an anaphylactic reaction, clinicians should immediately administer 1.0 mg/mL of epinephrine via the IM route in the anterolateral vastus lateralis muscle. Administration of IM epinephrine should be repeated every 5 to 15 minutes until the desired response is achieved.[22]

According to the 2019 ACIP report, HPV is responsible for an estimated 33,700 cancer cases annually in the United States. This includes 12,900 cases of oropharyngeal cancers among both men and women, 10,800 cases of cervical cancer among women, and 6,000 cases of anal cancer among both men and women. Although vaginal, vulvar, and penile cancers are relatively less frequent, they are also associated with HPV infection.[8] Clinicians should recognize that the burden of HPV-related mortality is significantly greater than the combined mortality caused by tetanus, diphtheria, pertussis, and meningococcal disease.[9] To support widespread vaccination efforts and increase the global prevention of diseases and dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, clinicians must increase patient awareness during wellness visits regarding the importance of HPV vaccination. Interprofessional team members should also educate their patients on the different cancers and avoidable precancerous lesions when immunized with 9vHPV. Patients must be urged to complete the recommended three-dose sequence of 9vHPV. Clinicians can increase vaccine compliance by scheduling follow-up visits in person. Further, clinics, pharmacies, and hospitals should implement standard operating procedures to prevent severe injury, such as safe vaccine administration spaces. Interventions that include healthcare education, tailored systems changes, feedback, and early initiation of the HPV vaccine may improve patient adherence and completion of vaccination schedules.[23] Moreover, healthcare professionals should be aware of and attentive to the acute onset of symptoms of an anaphylactic reaction. All healthcare team members should receive training in the administration of epinephrine auto-injectors. Clinicians should prescribe the HPV vaccine according to the latest ACIP and CDC recommendations. Nurses should administer and monitor for adverse reactions. Pharmacists should report adverse events following immunization by the Vaccine Adverse Event Reporting System (VAERS), which would enhance patient safety.[24] Interprofessional collaboration between clinicians and pharmacists facilitates improved outcomes with reduced adverse reactions, along with higher vaccination rates and increased public awareness regarding the significance of the 9vHPV vaccination.